Neuroendocrine Neoplasms: Genetics and Epigenetics

Jim Smith; Edward Barnett; Euan J Rodger; Aniruddha Chatterjee; Rathan M Subramaniam

doi:10.1016/j.cpet.2022.11.003

Neuroendocrine Neoplasms: Genetics and Epigenetics

PET Clin. 2023 Apr;18(2):169-187. doi: 10.1016/j.cpet.2022.11.003.

Authors

Jim Smith¹, Edward Barnett², Euan J Rodger², Aniruddha Chatterjee², Rathan M Subramaniam³

Affiliations

¹ Department of Pathology, Dunedin School of Medicine, University of Otago, PO Box 56, Dunedin 9054, New Zealand; Te Whatu Ora - Southern, Dunedin Public Hospital, 270 Great King Street, PO Box 913, Dunedin, New Zealand. Electronic address: jim.smith2@southerndhb.govt.nz.
² Department of Pathology, Dunedin School of Medicine, University of Otago, PO Box 56, Dunedin 9054, New Zealand.
³ Department of Medicine, Otago Medical School, University of Otago, PO Box 56, Dunedin 9054, New Zealand; Department of Radiology, Duke University, 2301 Erwin Rd, BOX 3808, Durham, NC 27705, USA.

PMID: 36858744
DOI: 10.1016/j.cpet.2022.11.003

Abstract

Neuroendocrine neoplasms (NENs) are a group of rare, heterogeneous tumors of neuroendocrine cell origin, affecting a range of different organs. The clinical management of NENs poses significant challenges, as tumors are often diagnosed at an advanced stage where overall survival remains poor with current treatment regimens. In addition, a host of complex and often unique molecular changes underpin the pathobiology of each NEN subtype. Exploitation of the unique genetic and epigenetic signatures driving each NEN subtype provides an opportunity to enhance the diagnosis, treatment, and monitoring of NEN in an emerging era of individualized medicine.

Keywords: Epigenetics; Genetics; Molecular landscape; Neuroendocrine neoplasms.

Publication types

Review

MeSH terms

Epigenesis, Genetic*
Humans
Neuroendocrine Tumors* / genetics
Precision Medicine